Relationship Between Hypertransmission Defect Size and Progression in Eyes with Intermediate Age-related Macular Degeneration

Author:

Sadda SriniVas1,Nanegrungsunk Onnisa,Corradetti Giulia1,Phinyo Phichayut,Choovuthayakorn JanejitORCID

Affiliation:

1. Doheny Eye Institute

Abstract

Abstract Objectives To determine the associations between the presence of various-sized hypertransmission defects (hyperTDs) and progression to incomplete retinal pigment epithelial (RPE) and outer retinal atrophy (iRORA) and complete RORA (cRORA) in eyes with intermediate age-related macular degeneration (iAMD).Methods Optical coherence tomography (OCT) data from consecutive iAMD patients, were retrospectively reviewed. All of iAMD eyes with or without iRORA (but not cRORA) at baseline were included. Graders evaluated the presence of hyperTDs at baseline (small: 63–124 µm; medium: 125–249 µm; large: ≥ 250 µm in diameter on choroidal en face OCT) and the progression two years later.Results Of the 145 eyes that not developed neovascular AMD at two years, the eyes that progressed to or developed iRORA or cRORA included 13 eyes (10.7%), 5 eyes (83.3%), 9 eyes (81.8%), and 6 eyes (85.7%) in the groups with no, small, medium, and large hyperTDs at baseline, respectively (P-value < 0.001). The odds ratios (95% CI) for progression were 41.6 (4.5–383.6), 37.4 (7.3–192.0), and 49.9 (5.6–447.1) in the small, medium, and large hyperTDs groups, compared to no hyperTDs (P-value ≤ 0.001). Eyes with ≥ 2 hyperTDs also showed more frequent progression than eyes with one or no hyperTDs (100% vs. 16.4%; P-value < 0.001).Conclusions While most iAMD eyes with no hyperTDs remained stable on OCT over two years, eyes with hyperTDs of any size appeared to be at a higher risk for progression. HyperTDs may provide an important OCT biomarker for identifying high-risk iAMD patients.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the right to sight: an analysis for the global burden of disease study;GBD 2019 Blindness and Vision Impairment Collaborators, on belhalf of Vision Loss Expert Group of the Global Burden of Disease Study;Lancet Glob Health,2021

2. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the anchor study;Brown DM;Ophthalmology,2009

3. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;Martin DF;N Engl J Med,2011

4. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the view studies;Schmidt-Erfurth U;Ophthalmology,2014

5. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: From bench to bedside;Campochiaro PA;Ophthalmology,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3